Mentor Capital, Inc. Acquires 20% of Cutting Edge Cancer Immunotherapy Company: Quantum Immunologics, Inc.

SAN DIEGO--(Business Wire)--
Mentor Capital, Inc. (Pink Sheets: MNTR) is pleased to announce that it is
providing equity funding to support Quantum Immunologics, Inc. (QI) to complete
their FDA authorized Phase I/II trials on metastatic breast cancer, which are
now underway (NCT00879489). QI holds exclusive license to patents that pertain
to certain therapeutic and diagnostic applications of the Oncofetal Antigen
(OFA), a universal marker found on all tested cancer lines but not found in
normal tissues. The current QI clinical approach is to externally process and
sensitize dendritic cells from the patient`s own blood to recognize the OFA in
their breast cancers as a marker for diseased tissue. The sensitized dendritic
cells are then re-injected into the patient to stimulate their body`s own immune
system to attack the cancerous cells in an effort to eradicate or stabilize the
patient`s disease. Dendreon (DNDN) utilizes a similar dendritic immunotherapy
approach, but focuses on a prostate-specific protein, through its Provenge
product.

In addition to providing $2.2 Million in funding to help support the FDA trials
through approximately February 2010, Mentor Capital has agreed to assist QI in
funding future strategic stock or cash acquisitions. Mentor will also stand by
as a preferred funding source for QI during later stage or additional trials. In
exchange for this financial support, Mentor Capital has received common stock in
QI reflecting a carried interest of 20%. At the current private placement price
for the QI shares, the acquisition of the QI position increases Mentor Capital
assets per share by $3.74 per share.

The Oncofetal Antigen - Immature Laminin Receptor patents are a product of 20
years and $30 Million of research at The University of South Alabama Medical &
Science Foundation and were primarily funded by the National Institute of
Health`s National Cancer Institute. The complete Quantum Immunologics corporate
story, including a summarizing video of the QI breast cancer treatment
methodology that is entering FDA trials, may be found at their company web site:
www.QuantumImmunologics.com. Comprehensive information on Mentor Capital,
including capital structure detail, can be found at: www.MentorCapital.com.
Level II quotes, news, financial information and trading charts may be
referenced at www.PinkSheets.com under the trading symbol MNTR.

Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated
by Reference from the MNTR Company Web Site above.

Mentor Capital, Inc.
Chet Billingsley, CEO
760-788-4700

Copyright Business Wire 2009